Țară: Malaezia
Limbă: engleză
Sursă: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
BUMETANIDE
DKSH MALAYSIA SDN BHD
BUMETANIDE
4ml mL
CENEXI
1. NAME OF THE MEDICINAL PRODUCT Burinex® Bumetanide Carefully read this insert before administering this product. It contains information about your treatment. If you have any doubt or you are not sure about something, please ask your physician or Pharmacist chemist. Keep this insert as you might need to read it again. Verify this product fully corresponds to the one prescribed by your physician. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Bumetanide 0.50 mg/ml Pack size: 5x4ml ampoules For the full list of excipients, see section 6.1. Not all pack sizes, strengths and formulations may be marketed Sale under prescription 3. PHARMACEUTICAL FORM Solution for injection Clear colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Burinex® is indicated whenever diuretic therapy is required in the treatment of oedema e.g. associated with congestive heart failure, cirrhosis of the liver, renal diseases including the nephrotic syndrome. Acute pulmonary oedema, drug induced fluid retention, and drug poisoning that can be treated by forced diuresis. Hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Usually 1–2 mg intravenously or intramuscularly. Pulmonary oedema: Initially 2 mg by intravenous injection. This can be repeated, if necessary, after 20 minutes. In those conditions in which an infusion appropriate, 2–5 mg may be given in 500 ml infusion fluid over 30–60 minutes. Renal failure: 2–10 mg in 500 ml infusion fluid given over a period of 30–60 minutes. Repeated, if required, at intervals of 6–8 hours. Drug poisoning with salicylates or barbiturates: Initially, 2 mg intravenously, followed by 1 mg every 4 hours. Totally, 7 mg in the course of 24 hours. The usual procedure for forced alkaline diuresis should be followed. Burinex® injection may be added to the commonly used infusion fluids based on glucose, sodium chloride, sodium bicarbonate, or potassium chloride. 4.3 CONTRAINDICATIONS • Hypersensitivity to formaldehyde (see Section 4.4). • Hypersensitivity to active substan Citiți documentul complet